drugset / Trial / NCT06478472
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
Recruiting
36 enrolled
The First Affiliated Hospital of Xiamen University
Chinese PLA General Hospital · collabFujian Cancer Hospital · collabGuangdong Provincial People's Hospital · collabJiangxi Provincial Cancer Hospital · collabNanfang Hospital, Southern Medical University · collabShanxi Province Cancer Hospital · collabThe First Hospital of Jilin University · collabThe Second Affiliated Hospital of Dalian Medical University · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
Orelabrutinib combined with rituximab (OR) therapy were used to assess the efficacy and safety for newly diagnosed Marginal zone cell lymphoma
Timeline
- Start
- 2024-06-23
- Primary completion
- 2027-06-23
- Completion
- 2027-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |